This NIDDK-sponsored Core Center of Excellence in Hematology (CCEH) provides cost effective, quality assured resources and expertise that enable individual investigators to isolate stem / progenitor cells, mark them, alter their gene expression, and accurately detect and quantitate their progeny in vitro and in vivo. The original application funded in 1999, contained 5 cores which have to date served 90+ investigators, in 18 States and 4 countries. These resources have continuously evolved to adapt new functions that anticipate and meet the needs of the research base, as shown by the addition of a new core. Therefore the current application proposes 6 cores. Core A, the Administrative Core, directed by Dr Beverly Torok-Storb provides scientific and budgetary oversight for all core activities. Core B, now a National Core for Large-Scale Cell Processing directed by Dr Shelly Heimfeld, adapts and/or develops technologies to optimally harvest, isolate, cryopreserve and analyze defined populations of human, canine, and non-human primate cells harvested from blood and marrow. Core C, Clonal Analysis directed by Dr Mike Harkey, provides reagents and methods for tracking stem cell progeny. Core D, Vector Production directed by Dr Hans Peter Kiem, provides existing and develops improved viral vectors and vector production technologies for gene transfer into cells. Core E, Xenograft Models, under the direction of Dr Irv Bernstein provides xenografting for in vivo functional analysis of stem/progenitor cell populations. Core F, the developing Canine Cell and Molecular Resources Core, directed by Dr Patrick Paddison, is a new core that serves to enhance the value of the canine large animal model for preclinical in vivo testing of cells and reagents, with particular emphasis given to developing canine specific RNA interference technologies. Finally, Core A is also responsible for oversight of a charge-back system to generate program income. This program income is used to enhance the cores but also to fund the Pilot &Feasibility (P&F) Studies Program and the Enrichment Program. During the past five years 30 P&F grants were awarded and 27 speakers were sponsored. Both programs significantly impact the 40 member research base by stimulating and supporting new research directions and facilitating new collaborations. The NIH-sponsored Hematology-related support of the research base exceeds $25 million in direct costs annually. This represents more than 80% of all grants awarded to the research base.

Public Health Relevance

Procuring adequate numbers of hematopoietic stem cells for research and applying the latest technologies to this research are often outside the financial reach and expertise of individual investigators. The NIDDK-sponsored Core Centers provide a mechanism whereby collaborative groups of investigators share resources to reduce costs while providing high quality state-of-the-art technologies and speeding progress.

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Center Core Grants (P30)
Project #
3P30DK056465-15S1
Application #
8704497
Study Section
Special Emphasis Panel (ZDK1-GRB-G (O3))
Program Officer
Bishop, Terry Rogers
Project Start
1999-09-15
Project End
2015-06-30
Budget Start
2013-09-01
Budget End
2014-06-30
Support Year
15
Fiscal Year
2013
Total Cost
$38,318
Indirect Cost
$2,838
Name
Fred Hutchinson Cancer Research Center
Department
Type
DUNS #
078200995
City
Seattle
State
WA
Country
United States
Zip Code
98109
King, Bryan; Boccalatte, Francesco; Moran-Crusio, Kelly et al. (2016) The ubiquitin ligase Huwe1 regulates the maintenance and lymphoid commitment of hematopoietic stem cells. Nat Immunol 17:1312-1321
Rosinski, Steven Lawrence; Stone, Brad; Graves, Scott S et al. (2016) Minor Antigen Vaccine-Sensitized DLI: In Vitro Responses Do Not Predict In Vivo Effects. Transplant Direct 2:e71
Rufener, Gregory A; Press, Oliver W; Olsen, Philip et al. (2016) Preserved Activity of CD20-Specific Chimeric Antigen Receptor-Expressing T Cells in the Presence of Rituximab. Cancer Immunol Res 4:509-19
Blau, C Anthony; Ramirez, Arturo B; Blau, Sibel et al. (2016) A Distributed Network for Intensive Longitudinal Monitoring in Metastatic Triple-Negative Breast Cancer. J Natl Compr Canc Netw 14:8-17
Turtle, Cameron J; Hanafi, Laïla-Aïcha; Berger, Carolina et al. (2016) Immunotherapy of non-Hodgkin's lymphoma with a defined ratio of CD8+ and CD4+ CD19-specific chimeric antigen receptor-modified T cells. Sci Transl Med 8:355ra116
Su, Wei; Kang, John; Sopher, Bryce et al. (2016) Recombinant adeno-associated viral (rAAV) vectors mediate efficient gene transduction in cultured neonatal and adult microglia. J Neurochem 136 Suppl 1:49-62
Yeung, Cecilia C S; Deeg, H Joachim; Pritchard, Colin et al. (2016) Jumping translocations in myelodysplastic syndromes. Cancer Genet 209:395-402
Adair, Jennifer E; Waters, Timothy; Haworth, Kevin G et al. (2016) Semi-automated closed system manufacturing of lentivirus gene-modified haematopoietic stem cells for gene therapy. Nat Commun 7:13173
Humbert, Olivier; Gisch, Don W; Wohlfahrt, Martin E et al. (2016) Development of Third-generation Cocal Envelope Producer Cell Lines for Robust Lentiviral Gene Transfer into Hematopoietic Stem Cells and T-cells. Mol Ther 24:1237-46
Toledo, Chad M; Ding, Yu; Hoellerbauer, Pia et al. (2015) Genome-wide CRISPR-Cas9 Screens Reveal Loss of Redundancy between PKMYT1 and WEE1 in Glioblastoma Stem-like Cells. Cell Rep 13:2425-39

Showing the most recent 10 out of 250 publications